EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

A Systematic Review of Renal Outcomes of Aldosterone Synthase Inhibitors Compared to Mineralocorticoid Receptor Antagonists

Girin Ray, Debmalya Sanyal

Archives of Endocrinology and Disorders · 15.06.2026 · 2 (2) · 1

DOI: 10.46889/aed.2026.2205 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Archives of Endocrinology and Disorders, online erschienen am 15.06.2026. Verfasst von Girin Ray und 1 weiteren Autor:innen. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysregulation of the Renin-Angiotensin-Aldosterone System (RAAS), particularly aldosterone excess, plays a central pathophysiological role in renal outcomes by causing sodium retention, vascular remodelling, inflammation and progressive organ damage. Resistant hypertension with further RAAS dysregulation has a significant impact on cardio-renal syndrome. The inhibition of this pathway has thus taken the centre stage in treatment interventions. The systematic review compared the effectiveness and safety of aldosterone synthase and mineralocorticoid receptor antagonists in renal outcomes across different populations including resistant hypertension. The PRISMA-guided approach was used and the database was broadly searched (PubMed, Scopus, Web of Science, the Cochrane Library) with the search restrictions being published within the period of 2020 and 2025. Studies that were eligible were randomized controlled trials, cohort studies and clinical trials that evaluated renal outcomes as well as adverse effects. Renal outcome data extracted included changes in eGFR (mL/min/1.73 m²) and urine ACR (mg/g) from baseline to end of follow-up in both ASI and MRA treatment groups. Studies were required to report at least one measure of renal function, including estimated Glomerular Filtration rate (eGFR) or urine Albumin-to-Creatinine Ratio (uACR), as primary or secondary outcome measures. MRA trials enrolled populations with significantly greater CKD burden, reflected by lower baseline eGFR (44.3-61.2 mL/min/1.7 3m²) and higher urine ACR (312-852 mg/g), demonstrating consistent long-term renoprotection with ACR reductions of 28-32% and stable eGFR values over 2.1-3.4 years of follow-up . In contrast, ASI trials enrolled patients with relatively preserved renal function at baseline (eGFR 68.9-74.1 mL/min/1.73 m²) and shorter follow-up durations of 8-24 weeks, yielding modest ACR reductions of 11-14% and stable eGFR values findings that are encouraging but insufficient to establish long-term renoprotective efficacy. ASIs exhibit superior tolerability compared to MRAs, with minimal endocrine adverse effects along with significant antihypertensive effects. In conclusion, the comparative renal outcome data currently favour MRAs, supported by robust long-term evidence of significant ACR reduction and stabilization of eGFR, while ASIs demonstrate encouraging early renal safety signals with early indications of ACR reduction and stabilization of eGFR that require validation through standardized, longer-duration trials with eGFR and urine ACR as pre-specified primary endpoints. Thus, there is promising evidence of the next-generation therapy of the aldosterone synthase inhibition, which also requires additional large-scale clinical research to prove its use in clinical practice.

Zitieren

APA

Ray, G., & Sanyal, D. (2026). A Systematic Review of Renal Outcomes of Aldosterone Synthase Inhibitors Compared to Mineralocorticoid Receptor Antagonists. Archives of Endocrinology and Disorders, 2(2), 1. https://doi.org/10.46889/aed.2026.2205

Vancouver

Ray G, Sanyal D. A Systematic Review of Renal Outcomes of Aldosterone Synthase Inhibitors Compared to Mineralocorticoid Receptor Antagonists. Archives of Endocrinology and Disorders. 2026;2(2):1. doi:10.46889/aed.2026.2205

BibTeX
@article{Ray2026,
  author = {Ray, Girin and Sanyal, Debmalya},
  title = {A Systematic Review of Renal Outcomes of Aldosterone Synthase Inhibitors Compared to Mineralocorticoid Receptor Antagonists},
  journal = {Archives of Endocrinology and Disorders},
  year = {2026},
  volume = {2},
  number = {2},
  pages = {1},
  doi = {10.46889/aed.2026.2205}
}
Kostenlos starten →